Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer
Status:
Withdrawn
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary
for tumor cell growth. Monoclonal antibodies such as trastuzumab can locate tumor cells and
either kill them or deliver tumor-killing substances to them without harming normal cells.
Combining tipifarnib with trastuzumab may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining tipifarnib with trastuzumab
in treating patients who have metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio